An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection
- PMID: 2217178
- PMCID: PMC54769
- DOI: 10.1073/pnas.87.19.7472
An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection
Abstract
The activity of the human immunodeficiency virus (HIV) protease is essential for processing of the gag-pol precursor proteins and maturation of infectious virions. We have prepared a peptidomimetic inhibitor, U-75875, that inhibited HIV-1 gag-pol protein processing in an essentially irreversible manner. Noninfectious virus particles produced in the presence of the drug contained gag precursors and were morphologically immature. In human peripheral blood mononuclear cells and in a continuous cell line, U-75875 completely blocked HIV replication; in the latter case, no spread occurred over a period of 4 weeks. U-75875, on a molar basis, was as potent as 3'-azido-3'-deoxythymidine in blocking HIV-1 replication in human lymphocytes and also inhibited HIV-2 and simian immunodeficiency virus proteases, demonstrating that it has broad activity. These results provide further evidence for the therapeutic potential of protease inhibitors in HIV infection.
Similar articles
-
CGP 53437, an orally bioavailable inhibitor of human immunodeficiency virus type 1 protease with potent antiviral activity.Antimicrob Agents Chemother. 1993 Oct;37(10):2087-92. doi: 10.1128/AAC.37.10.2087. Antimicrob Agents Chemother. 1993. PMID: 8257128 Free PMC article.
-
A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.Science. 1990 Jan 26;247(4941):454-6. doi: 10.1126/science.2405486. Science. 1990. PMID: 2405486
-
A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation.Dis Markers. 1990 May-Jun;8(3):162-3. Dis Markers. 1990. PMID: 2125537 No abstract available.
-
HIV proteinase inhibitors.Biochem Soc Trans. 1992 May;20(2):513-6. doi: 10.1042/bst0200513. Biochem Soc Trans. 1992. PMID: 1397651 Review. No abstract available.
-
Empirical and rational approaches for development of inhibitors of the human immunodeficiency virus--HIV-1.Pharmacol Ther. 1993 Nov;60(2):315-29. doi: 10.1016/0163-7258(93)90013-4. Pharmacol Ther. 1993. PMID: 8022862 Review.
Cited by
-
Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5286-90. doi: 10.1073/pnas.89.12.5286. Proc Natl Acad Sci U S A. 1992. PMID: 1608936 Free PMC article.
-
Effects of PRE and POST therapy drug-pressure selected mutations on HIV-1 protease conformational sampling.FEBS Lett. 2014 Aug 25;588(17):3123-8. doi: 10.1016/j.febslet.2014.06.051. Epub 2014 Jun 28. FEBS Lett. 2014. PMID: 24983495 Free PMC article.
-
Recovery of infectious human immunodeficiency virus type 1 after fusion of defectively infected clones of U-937 cells.J Virol. 1991 Oct;65(10):5589-92. doi: 10.1128/JVI.65.10.5589-5592.1991. J Virol. 1991. PMID: 1895407 Free PMC article.
-
Monitoring processed, mature Human Immunodeficiency Virus type 1 particles immediately following treatment with a protease inhibitor-containing treatment regimen.AIDS Res Ther. 2005 Apr 12;2(1):2. doi: 10.1186/1742-6405-2-2. AIDS Res Ther. 2005. PMID: 15826302 Free PMC article.
-
Small-molecule inhibition of human immunodeficiency virus type 1 replication by specific targeting of the final step of virion maturation.J Virol. 2004 Jan;78(2):922-9. doi: 10.1128/jvi.78.2.922-929.2004. J Virol. 2004. PMID: 14694123 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources